New approach aims to keep transplant working longer for blood cancer patients
NCT ID NCT03850418
Summary
This study is testing whether giving the drug azacitidine after a stem cell transplant can help maintain the donor's healthy cells in patients with blood cancers like AML and MDS. The goal is to reduce the risk of the cancer returning by preventing the patient's own cells from taking over again. Researchers are enrolling 43 adults who have had a transplant and are showing early signs that the donor cells might be decreasing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henry ford hospital
RECRUITINGDetroit, Michigan, 48202, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.